

1 **SARS-CoV-2 anti-spike antibody levels following second dose of ChAdOx1 nCov-19 or BNT162b2 in**
2 **residents of long-term care facilities in England (VIVALDI)**

3 **SARS-CoV-2 antibodies in long-term care**

4 Oliver Stirrup*, Maria Krutikov*, Gokhan Tut*, Tom Palmer, David Bone, Rachel Bruton, Chris Fuller,
5 Borscha Azmi, Tara Lancaster, Panagiota Sylla, Nayandeep Kaur, Eliska Spalkova, Christopher Bentley,
6 Umayr Amin, Azar Jadir, Samuel Hulme, Rebecca Giddings, Hadjer Nacer-Laidi, Verity Baynton, Aidan
7 Irwin-Singer, Andrew Hayward, Paul Moss, Andrew Copas, Laura Shallcross

8 *authors contributed equally

9 M. Krutikov MRCP, H. Nacer-Laidi PhD, B.Azmi MSc, C. Fuller MSc, R. Giddings DFPH, L. Shallcross PhD
10 UCL Institute of Health Informatics, London, NW1 2DA, United Kingdom

11 O. Stirrup PhD, A. Copas PhD, T. Palmer MSc

12 UCL Institute for Global Health, London, WC1N 1EH, United Kingdom

13 A. Hayward MD

14 UCL Institute of Epidemiology & Health Care, London, WC1E 7HB, United Kingdom

15 G. Tut PhD, D. Bone D, R. Bruton PhD, T. Lancaster PhD, P. Sylla MSc, N. Kaur MSc, E. Spalkova MSc, C.
16 Bentley BSc, U. Amin MSc, A. Jadir MSc, S. Hulme MSc, P. Moss PhD

17 Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, United
18 Kingdom

19 A. Hayward MD

20 Health Data Research UK, London, United Kingdom

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America and HIV Medicine Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

1 A. Irwin-Singer MA, V. Baynton
2 Department of Health and Social Care, London, SW1H 0EU, United Kingdom

3 **Correspondence to:** Dr Maria Krutikov,

4 UCL Institute of Health Informatics, 222 Euston Rd, London NW1 2DA;

5 m.krutikov@ucl.ac.uk

6 [Alternative contact: Dr Oliver Stirrup](#)

7 Institute for Global Health, University College London, Mortimer Market Centre, off Capper Street,
8 London WC1E 6JB, UK.
9 oliver.stirrup@ucl.ac.uk

10 Short summary: 40 words

11 Antibody responses to vaccination in older residents of long-term care facilities are comparable to those
12 in the general population. Although antibody levels are initially greater they fall more rapidly following
13 Pfizer-BioNTech vaccination than Oxford-AstraZeneca. Prior infection enhances responses in all.

14

1 **Abstract**

2

3 General population studies have shown strong humoral response following SARS-CoV-2 vaccination with
4 subsequent waning of anti-spike antibody levels. Vaccine-induced immune responses are often
5 attenuated in frail and older populations, but published data are scarce. We measured SARS-CoV-2 anti-
6 spike antibody levels in Long-Term Care Facility residents and staff following second vaccination dose
7 with Oxford-AstraZeneca or Pfizer-BioNTech. Vaccination elicited robust antibody responses in older
8 residents, suggesting comparable levels of vaccine-induced immunity to that in the general population.
9 Antibody levels are higher after Pfizer-BioNTech vaccination but fall more rapidly compared to Oxford-
10 AstraZeneca recipients and are enhanced by prior infection in both groups.

11

12 **Key words:** COVID-19, long-term care facilities, vaccination, antibodies, waning

13

1 **Introduction**

2 Residents of Long-Term Care Facilities (LTCF) have experienced extremely high rates of SARS-CoV-2
3 infection and mortality[1]. Since December 2020, LTCF staff and residents in England have been
4 prioritised for vaccination against SARS-CoV-2, with initial roll-out primarily using the mRNA-based
5 BNT162b2 (Pfizer-BioNTech) and adenoviral vector-based ChAdOx1 (Oxford-AstraZeneca) vaccines[2].

6 Vaccine effectiveness in the general population has been demonstrated for at least six months following
7 second dose administration[3,4]. However, data are limited on the duration and magnitude of
8 protection afforded by vaccination in LTCF residents. Furthermore, LTCF residents are especially
9 vulnerable to severe outcomes following infection due to frailty, high rates of co-morbidity, poorer
10 nutritional status, and age-related dampening of immune responses (immune-senescence) which impact
11 on vaccine-induced immunity[5].

12 Current SARS-CoV-2 vaccines target the viral spike protein, and anti-spike antibody levels are an
13 important correlate of vaccine efficacy[6]. Early studies are encouraging and suggest robust cellular and
14 humoral responses in the initial months following vaccination amongst LTCF residents, particularly in
15 previously-infected individuals[6,7]. However, studies from the general population have reported
16 waning of antibody titres in the six months following vaccination, particularly in people older than 65
17 years[8–10]. We investigated quantitative anti-spike antibody titres amongst LTCF staff and residents in
18 England over the first nine months following second vaccination dose.

19 **Methods**

20 VIVALDI (ISRCTN 14447421) is a prospective cohort study of residents and staff of LTCFs in England[11].

21 Eligible individuals from participating LTCFs provide written informed consent for study participation

22 and consultees are sought for residents lacking capacity to consent. Participants have undergone up to

1 five rounds of blood sampling at eight-week intervals between 11 June 2020 and 22 October 2021. As
2 part of the national pandemic response, all LTCF staff and residents regularly submit nasopharyngeal
3 swabs for SARS-CoV-2 PCR testing (monthly in residents, weekly in staff) with additional testing during
4 outbreaks[12].

5 Blood samples undergo SARS-CoV-2 nucleocapsid IgG testing using the Abbott ARCHITECT semi-
6 quantitative immunoassay (Maidenhead, UK). Quantitative antibody titres against SARS-CoV-2 spike and
7 nucleocapsid IgG are measured using the Meso Scale Diagnostics (MSD) V-PLEX COVID-19 Respiratory
8 Panel 2 kit (Rockville, MD, USA). Anti-nucleocapsid antibodies are used to identify immune responses
9 stimulated by prior infection. MSD observations were included from ≥ 21 days after second vaccine dose
10 administration, corresponding to peak antibody response[4], up until date of third vaccine dose where
11 recorded. Only individuals with data on demographic characteristics and vaccinations were included in
12 this analysis and most could also be linked to full testing history (Appendix S1).

13 To model post-vaccination MSD assay anti-spike antibody levels, individuals were categorised as either
14 having 'no evidence of prior infection' or 'evidence of prior infection'. The latter group included
15 individuals with at least one record of an active infection defined by PCR or point-of-care lateral flow
16 test (LFT) positivity or hospitalisation with COVID-19 prior to second vaccine dose, and those with
17 presence of anti-nucleocapsid antibodies on either Abbott or MSD assay. To exclude breakthrough
18 infections which may have boosted antibody levels, observations with active infection recorded after
19 second vaccine dose but prior to index date were dropped from analysis, as were observations following
20 post-vaccination anti-nucleocapsid seroconversion.

21 An index value ≥ 0.8 defined Abbott anti-nucleocapsid assay positivity[13]. A threshold of 1200 AU/mL
22 was used for MSD anti-nucleocapsid assay, which had a specificity of 96% (48/50) using pre-pandemic
23 blood samples.

1 VIVALDI has been granted research ethics approval by the South Central-Hampshire B Research Ethics
2 Committee (ref:20/SC/0238).

3 *Statistical analysis*

4 Log₁₀-transformed MSD anti-spike levels were modelled using linear mixed effects models. Time was
5 centred at 21 days after second vaccine dose, with random intercept and slope terms for each
6 participant. This approach allows for the analysis of all available data within a single statistical model
7 and can accommodate irregular numbers and timings of measurements for each participant. Intercept
8 terms from the model correspond to estimated peak antibody levels and slope terms correspond to rate
9 of decline over time on the log-scale.

10 An initial model was fitted with independent effects assumed for vaccine type, sex, staff/resident status
11 and prior SARS-CoV-2 infection, followed by a model with interaction terms between vaccine type and
12 each other variable. A further model was considered with addition of subject-age (centred at 70 years)
13 as a linear predictor of both intercept and slope by vaccine type. Half-life values were calculated based
14 on estimated time to drop in mean log₁₀ antibody level of log₁₀(0.5). Formal sample size calculation
15 was not undertaken.

16 **Results**

17 We describe 558 anti-spike antibody (MSD) results from 402 LTCF residents and 759 from 632 staff. 774
18 people had one observation, 237 had two and 23 had three. Median age was 86 (IQR 78-91) years for
19 residents and 50 (IQR 37-58) years for staff. Samples included in the analysis were collected between 15
20 March and 22 October 2021. The median time between first and second dose was 74 days (IQR 66-77
21 days) for residents and 74 days (IQR 63-77 days) for staff (P=0.15 for difference between groups on
22 Mann-Whitney test). Median time from second vaccine dose to blood sample was 136 days (IQR 104-

1 170, range 21-280). Four observations from four residents and four from three staff were dropped from
2 analysis as they followed detection of an active breakthrough infection. Eight residents and eight staff
3 each had one observation excluded because of indirect evidence of breakthrough infection (i.e.,
4 appearance of anti-nucleocapsid antibodies).

5 The interaction model, allowing different effects by vaccine type, was found to provide better fit to the
6 data than the simpler independent effects model ($P=0.01$, likelihood ratio test (LRT)), and a further
7 improvement was found by adding age as linear predictor of peak antibody levels and slope ($P=0.03$,
8 LRT).

9 Based on findings from the mixed-effects model, peak antibody titres were greater in Pfizer-B recipients
10 than in Oxford-AZ recipients ($\times 7.9$, 95%CI 3.6-17.0; $P<0.01$), although we also observed a steeper annual
11 decline in this group ($\times 0.08$ at 12 months vs equivalent decline from peak, 0.01-0.72; $P=0.02$) (Table 1,
12 Figure 1). Prior infection with SARS-CoV-2 was associated with higher peak antibody levels and slower
13 decline for both Pfizer-B (peak $\times 2.8$, 1.9-4.1; $P<0.01$) and Oxford-AZ ($\times 4.8$, 95%CI 3.2-7.1; $P<0.01$)
14 recipients. Male sex was associated with slightly higher peak in antibody levels for both vaccines (not
15 statistically significant) but steeper decline, particularly for Oxford-AZ recipients. LTCF resident vs staff
16 status was not associated with any statistically significant difference in peak antibody level or slope of
17 decline. However, increasing age was associated with lower antibody peak for Oxford-AZ recipients.
18 'Half-life' estimates of antibody decline were in the range 60-120 days for most subgroups, with values
19 >6 months in female Oxford-AZ recipients with prior infection, but 95% CIs were wide (Table S2).

20 **Discussion**

21 We present post-vaccination serological data from a large cohort of frail LTCF residents in England, a
22 group in whom published data are scarce. Our findings are broadly consistent with longitudinal studies

1 conducted in the general population and healthcare workers[8,10] which is reassuring given the
2 vulnerability of LTCF residents to SARS-CoV-2 infection.

3 Consistent with previous studies, we find higher peak antibody titres following vaccination with Pfizer
4 compared to Oxford-AZ[9,10]. Wei et al reported on anti-spike antibody waning in ~100,000 Oxford-AZ
5 and ~55,000 Pfizer-B vaccine recipients, sampled through the Coronavirus Infection Survey (CIS)[10]. For
6 Oxford-AZ they found peak antibody levels were higher in those with prior infection, and slightly lower
7 in males and younger ages. Peak antibody levels were greater in Pfizer-B recipients compared with
8 Oxford-AZ but were lower at older ages and for males[10].

9 The collection of samples up to 9 months after vaccination allowed us to assess the rate of spike-specific
10 antibody decline from peak value. The mean half-life of antibody decline was reported as 85 days (95%CI
11 84-86) after Oxford-AZ in the CIS study, and this was increased to 131 days in those with prior infection.
12 They found comparable mean half-life after Pfizer-B of 101 days (100-102) which was extended to 188
13 days in those with prior infection[10]. Our data also revealed mean half-life in the range 60-120 days but
14 did not uncover significant variation in the rate of antibody decline between LTCF staff and residents.
15 Analysis of >8500 community-dwelling infection-naïve adults also found no difference in rates of waning
16 in donors aged ≥ 65 years although peak titres declined with age[9].

17 Our study is consistent in finding higher peak levels and longer half-life associated with prior infection
18 for both vaccine types, and higher peak levels following Pfizer vaccination. However, we find no
19 difference between staff and residents besides a lower peak antibody response in older Oxford-AZ
20 recipients. The level of exposure to infection was much greater in LTCFs than in the community, [1] and
21 those residents who survived infection are likely to have more robust immunological responses to
22 vaccination than their community-dwelling peers who are included in studies of the general population.

1 Overall, our results are encouraging and add to a body of evidence suggesting strong humoral and
2 cellular responses to vaccination amongst LTCF residents[14].

3 Our study is limited by a modest sample size, so there is uncertainty regarding the presence and
4 magnitude of observed effects. It is also possible that some individuals labelled as infection-naïve may
5 have waned below the positivity threshold following infection early in the pandemic[15]. To account for
6 this, we used a lower Abbott positivity threshold and included MSD results in defining “prior-exposure”,
7 but we cannot determine the chronology of infection in anti-nucleocapsid antibody positive participants.
8 As the analysis was carried out over a period of relatively low community transmission, it is unlikely that
9 antibody titres have been boosted by undetected breakthrough infections following second dose
10 vaccination. Finally, we have only described humoral responses to vaccination; analyses in LTCF staff
11 and residents of vaccine-induced cellular immune responses and functional measures of immunity such
12 as neutralization antibody titres are underway by our group and others.

13 Insights into the magnitude and duration of vaccine-induced immune responses are crucial to inform the
14 timing of booster vaccination, particularly with the emergence of novel variants such as Omicron. Our
15 findings reveal that current COVID-19 vaccines retain high immunogenicity in the LTCF setting but
16 factors such as peak antibody response and rate of antibody waning, which will be used to guide the
17 need for future vaccinations, are strongly influenced by vaccine regimen and prior infection status.
18 Ongoing assessment of humoral immunity will be important in order to guide introduction of optimal
19 booster regimens that maintain immunity over the longer term.

20 **Acknowledgements**

21 We thank the staff and residents in the LTCFs that participated in this study and Mark Marshall at NHS
22 England who pseudonymised the electronic health records. This work is independent research funded
23 by the Department of Health and Social Care (COVID-19 surveillance studies). MK is funded by a

1 Wellcome Trust Clinical PhD Fellowship (222907/Z/21/Z). LS is funded by a National Institute for Health
2 Research Clinician Scientist Award (CS-2016-007). AH is supported by Health Data Research UK (LOND1),
3 which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research
4 Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief
5 Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care
6 Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland),
7 British Heart Foundation, and Wellcome Trust. The views expressed in this publication are those of the
8 authors and not necessarily those of the NHS, Public Health England, or the Department of Health and
9 Social Care.

10 LS, TP, AC, and OS report grants from the Department of Health and Social Care during the conduct of
11 the study and LS is a member of the Social Care Working Group, which reports to the Scientific Advisory
12 Group for Emergencies. AIS and VB are employed by the Department of Health and Social Care who
13 funded the study. AH reports funding from the Covid Core Studies Programme is a member of the New
14 and Emerging Respiratory Virus Threats Advisory Group at the Department of Health and Environmental
15 Modelling Group of the Scientific Advisory Group for Emergencies. All other authors declare no
16 competing interests.

17

1 References

- 2 1. ECDC. Surveillance data from public online national reports on COVID-19 in long-term care facilities.
3 2021.
- 4 2. GOV.UK. Vaccine update: issue 315, December 2020, COVID-19 special edition - GOV.UK.
- 5 3. Andrews N, Tessier E, Stowe J *et al.* Vaccine effectiveness and duration of protection of Comirnaty,
6 Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. *medRxiv*
7 2021:2021.09.15.21263583.
- 8 4. Eyre DW, Lumley SF, Wei J *et al.* Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and
9 Oxford–AstraZeneca vaccines by previous infection status. *Clinical Microbiol Infect* 2021;**27**:1516.e7-
10 1516.e14.
- 11 5. Castro-Herrera VM, Lown M, Fisk HL *et al.* Relationships Between Age, Frailty, Length of Care Home
12 Residence and Biomarkers of Immunity and Inflammation in Older Care Home Residents in the United
13 Kingdom. *Front Aging* 2021;**0**:2.
- 14 6. Feng S, Phillips DJ, White T *et al.* Correlates of protection against symptomatic and asymptomatic
15 SARS-CoV-2 infection. *Nat Med* 2021 27:11 2021;**27**:2032–40.
- 16 7. Parry H, Bruton R, Tut G *et al.* Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-
17 19 at 5–6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis. *Lancet*
18 *Healthy Longev* 2021;**2**:e554–60.
- 19 8. Levin EG, Lustig Y, Cohen C *et al.* Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine
20 over 6 Months. *NEJM* 2021;**385**:e84.
- 21 9. Aldridge RW, Yavlinsky A, Nguyen V *et al.* Waning of SARS-CoV-2 antibodies targeting the Spike
22 protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of
23 breakthrough infections: analysis of the Virus Watch community cohort. *medRxiv*
24 2021:2021.11.05.21265968.
- 25 10. Wei J, Pouwels KB, Stoesser N *et al.* SARS-CoV-2 anti-spike IgG antibody responses after second dose
26 of ChAdOx1 or BNT162b2 and correlates of protection in the UK general population. *medRxiv*
27 2021:2021.09.13.21263487.

- 1 11. Krutikov M, Palmer T, Donaldson A *et al.* Study Protocol: Understanding SARS-Cov-2 infection,
2 immunity and its duration in care home residents and staff in England (VIVALDI). *Wellcome Open Res*
3 2020;**5**:232.
- 4 12. GOV.UK. Coronavirus (COVID-19) testing in adult care homes. 2021.
- 5 13. Ainsworth M, Andersson M, Auckland K *et al.* Performance characteristics of five immunoassays for
6 SARS-CoV-2: a head-to-head benchmark comparison. *The Lancet Infect Dis* 2020;**20**:1390–400.
- 7 14. Tut G, Lancaster T, Krutikov M *et al.* Profile of humoral and cellular immune responses to single
8 doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes
9 (VIVALDI): an observational study. *Lancet Healthy Longev* 2021;**2**:e544–53.
- 10 15. Krutikov M, Palmer T, Tut G *et al.* Prevalence and duration of detectable SARS-CoV-2 nucleocapsid
11 antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI
12 study): prospective cohort study in England. *Lancet Healthy Longev* 2021;**0**:2021.

13

14

ACCEPTED MANUSCRIPT

- 1 **Table 1** Regression coefficients from final statistical mixed-effects model for anti-spike antibody levels
 2 from 21 days following second vaccine dose, fitted to log10-transformed data

	<i>n</i> , <i>n</i> (%) or median (IQR)	Intercept[†] (95%CI); P	Slope (95% CI); P [annual change]
Reference coefficients‡		4.12 (3.86 to 4.38)	-0.67 (-1.48 to 0.14)
<i>Oxford-AZ recipients</i>	493	Difference in intercept (95%CI)#; P	Difference in slope (95%CI)**; P
Prior infection (yes vs no)	246 (49.9)	0.68 (0.5 to 0.85); <0.01	0.50 (-0.01 to 1.01); 0.06
LTCF resident (vs staff)	251 (50.9)	0.22 (-0.14 to 0.59); 0.23	-0.45 (-1.58 to 0.67); 0.43
Male (vs female)	105 (21.3)	0.17 (-0.05 to 0.39); 0.13	-0.69 (-1.32 to -0.05); 0.03
Age (per 10y greater than 70)	67 (48–87)	-0.10 (-0.18 to -0.02); 0.01	0.16 (-0.09 to 0.42); 0.20
<i>Pfizer-B. recipients</i>	534	Difference in intercept (95%CI)#; P	Difference in slope (95%CI)**; P

Difference vs Oxford-AZ¶		0.90 (0.56 to 1.23); <0.01	-1.09 (-2.04 to -0.14); 0.02
Prior infection (yes vs no)	306 (57.3)	0.44 (0.27 to 0.61); <0.01	0.43 (0.01 to 0.85); 0.04
LTCF resident (vs staff)	147 (27.5)	-0.05 (-0.36 to 0.26); 0.74	0.06 (-0.7 to 0.82); 0.87
Male (vs female)	94 (17.6)	0.11 (-0.1 to 0.31); 0.31	-0.23 (-0.72 to 0.26); 0.36
Age (per 10y greater than 70)	56 (44–71)	-0.01 (-0.08 to 0.06); 0.76	-0.06 (-0.23 to 0.11); 0.49

1 LTCF, long-term care facility.

2 *% calculated using number with same vaccine type as denominator.

3 †Representing average peak value at 21 days after second vaccine dose.

4 ‡Values for Oxford-AZ recipient female staff member at 70 years of age without prior infection. ¶Taken
5 alone, represents the difference for female staff member at 70 years of age without prior infection.

6 #10^x gives multiplicative difference in intercept associated with each factor.

7 **10^x gives multiplicative difference in value at 12 months from peak level.

1 **Figure 1:** Log-transformed MSD values for anti-spike antibody levels in relation to the time from second
2 vaccine dose, divided by vaccine type and staff/resident status, and colour-coded by prior infection
3 category (red: evidence of prior infection; green: no evidence of prior infection). Individual observations
4 are shown as dots, with those from the same person linked by lines. The bold straight lines show
5 regression fits from a statistical model (omitting age and sex) to estimate trends in each group.


6 **Data sharing**

7 De-identified test results and limited metadata will be made available for use by researchers in future
8 studies, subject to appropriate research ethical approvals once the VIVALDI study cohort has been
9 finalised. These datasets will be accessible via the Health Data Research UK Gateway.

10

ACCEPTED MANUSCRIPT

1



2

3

4

Figure 1
165x128 mm (9.9 x DPI)